Peer-Reviewed Publications

CPCE investigators are international experts in their clinical effectiveness-related fields, and have authored hundreds of pediatric research articles in leading peer-reviewed journals. From here you can access CPCE journal article abstracts by author, title, or year.

Found 43 results
Author Title [ Year(Desc)]
Filters: Author is Alonzo, Todd A  [Clear All Filters]
2015
Miller TP, Troxel AB, Li Y, et al. "Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group." Pediatr Blood Cancer. 2015;62(7):1184-9.
Getz KD, Li Y, Alonzo TA, et al. "Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group." Pediatr Blood Cancer. 2015;62(10):1775-81.
Vujkovic M, Attiyeh EF, Ries RE, et al. "Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group." Cancer Genet. 2015;208(7-8):408-13.
Kutny MA, Alonzo TA, Gamazon ER, et al. "Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group." Leukemia. 2015;29(12):2424-6.
Tarlock K, Alonzo TA, Gerbing RB, et al. "Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group." Clin. Cancer Res.. 2015.
Li Y, Hall M, Fisher BT, et al. "Merging Children's Oncology Group Data with an External Administrative Database Using Indirect Patient Identifiers: A Report from the Children's Oncology Group." PLoS ONE. 2015;10(11):e0143480.
Johnston D, Gerbing R, Alonzo TA, et al. "Patient-Reported Outcome Coordinator Did Not Improve Quality of Life Assessment Response Rates: A Report from the Children's Oncology Group." PLoS ONE. 2015;10(4):e0125290.
2017
Lamba JK, Chauhan L, Shin M, et al. "CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531." J. Clin. Oncol.. 2017:JCO2016712513.
Miller TP, Li Y, Kavcic M, et al. "Center-level variation in accuracy of adverse event reporting in a clinical trial for pediatric acute myeloid leukemia: A report from the Children's Oncology Group." Haematologica. 2017.
Johnston DL, Alonzo TA, Gerbing RB, et al. "Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group." Pediatr Blood Cancer. 2017.
Tarlock K, Alonzo TA, Loken MR, et al. "Disease Characteristics and Prognostic Implications of Cell Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group." Clin. Cancer Res.. 2017.
Guest EM, Aplenc R, Sung L, et al. "Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials, AAML03P1 and AAML0531." Blood. 2017.
Vujkovic M, Attiyeh EF, Ries RE, et al. "Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report." Blood. 2017;129(23):3051-8.
Lim EL, Trinh DL, Ries RE, et al. "MicroRNA Expression-Based Model Indicates Event-Free Survival in Pediatric Acute Myeloid Leukemia." J. Clin. Oncol.. 2017:JCO2017747451.
Hanley MJ, Mould DR, Taylor TJ, et al. "Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients: Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range." J Clin Pharmacol. 2017.

Pages